Aitia, Pancreatic Cancer Action Network Strike Drug Collaboration Deal
Joint venture aims to drive new discoveries and improve patient outcomes.
In a company press release, Aitia announced a collaboration with the Pancreatic Cancer Action Network (PanCAN) focused on accelerating drug discovery and development. Through applying PanCAN's Spark health data platform, Atita intends to integrate de-identified human multi-omic data to create gemini digital twins, that will serve a wide range of applications, including the discovery of novel targets and biomarkers, simulation of drug candidates, identification of ideal patient subpopulations for clinical trials, and the determination of optimal drug combinations.
"Unraveling the complex genetic and molecular circuitry of Pancreatic Cancer is critical to the discovery of the next generation of drugs that can significantly increase the survival rate of patients," said Colin Hill, CEO, co-founder, Aitia. "We believe our Gemini Digital Twins, coupled with PanCAN's robust de-identified human multi-omic data, stand to increase efficacy in early research, ultimately leading to the discovery and development of breakthrough drugs. Collaborating with PanCAN is a pivotal milestone in our mission, as we envision reshaping the panorama of pancreatic cancer treatment by harnessing the potential of multi-omic patient data, Causal AI and Digital Twins".
Reference: Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient Data into Digital Twins to Drive New Discoveries and Improve Patient Outcomes. PR Newswire. September 27, 2023. Accessed September 28, 2023. https://www.prnewswire.com/news-releases/aitia-and-pancreatic-cancer-action-network-partner-to-transform-de-identified-multi-omic-patient-data-into-digital-twins-to-drive-new-discoveries-and-improve-patient-outcomes-301940556.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
